Table 3.
Cerebrospinal fluid biomarker findings
| Change from baseline at week 104 | Placebo | Gantenerumab 105 mg | Gantenerumab 225 mg | ||
|---|---|---|---|---|---|
| Change (%), median (Q1, Q3) | Change (%), median (Q1, Q3) | p Value vs placebo | Change (%), median (Q1, Q3) | p Value vs placebo | |
| Aβ42, pg/ml |
n = 72 −0.85% (−15.31, 21.03) |
n = 71 −1.06% (−19.33, 25.88) |
0.98 |
n = 66 7.55% (−13.96, 35.09) |
0.09 |
| t-tau, pg/ml |
n = 72 2.04% (−4.56, 8.72) |
n = 71 −1.08% (−7.65, 5.86) |
0.05 |
n = 66 −2.91% (−8.54, 3.40) |
0.02 |
| p-tau, pg/ml |
n = 72 0.08% (−3.91, 6.49) |
n = 71 −5.61% (−11.07, 0.97) |
≤ 0.001 |
n = 66 −7.15% (−14.48, −2.41) |
≤ 0.001 |
| Neurogranin, pg/ml |
n = 65 −3.24% (−20.64, 12.27) |
n = 66 −4.58% (−19.89, 10.13) |
0.79 |
n = 63 −11.76% (−23.69, 6.48) |
0.18 |
Abbreviations: Aβ Amyloid-beta, p-tau Phosphorylated tau, t-tau Total tau